tiprankstipranks
Trending News
More News >
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541)
:1541
Hong Kong Market
Advertisement

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) Revenue

Compare
0 Followers

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Revenue

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had a revenue of 39.41M in the quarter ending Dec 31, 2024, with 0.00%. This bring the company's revenue in the last twelve months to 79.18M, Decreased 99.10%. In the fiscal year ending Dec 31, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H had annual revenue of 74.15M with 19109.59% growth.
Revenue (ttm)
79.18M
Revenue Growth
18989.90%
P/S Ratio
102.78
Revenue/Employee
HK$475,314
Employees
156
Market Cap
HK$7.62B

Revenue Chart

Revenue History
Fiscal End Date
Revenue
Change
Growth
Dec 31, 2024
74.15M73.76M+19,109.59%
Dec 31, 2023
386.00K-152.00K-28.25%
Dec 31, 2022
538.00K-4.53M-89.38%
Dec 31, 2021
5.07M
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis